It is an ultra-short-acting selective β1-receptor blocker of the aryloxypropylamine class. It inhibits β1-receptors mainly by competing for catecholamine binding sites. It has the effects of slowing resting and exercise heart rates, lowering blood pressure, and myocardial oxygen consumption. At the same time, it has the characteristics of fast onset, high bioavailability, short half-life, accurate efficacy, and low side effects. It is currently mainly used in the clinical treatment of supraventricular arrhythmia and acute myocardial ischemia, and is used in the treatment of acute myocardial infarction, It also has obvious effects on unstable angina pectoris and postoperative hypertension.